Improving cell-based bioassay efficiencies for cell & gene therapies
Thursday 25 September 2025
07:00 [PDT] 10:00 [EDT] 15:00 [BST]
Catch up with Labcorp’s method development expert Amruta Kale, to get the inside line on their forward-thinking bioassay approaches and their applications in the development of cell and gene therapies.
This webinar will discuss the key challenges faced in the utilization of cell-based bioanalytical assays to support cell and gene therapies, a forward-thinking approach to drive client efficiencies for these newer modalities, and key learnings surrounding Labcorp’s efforts to use SVAR iLite® technology for AAV gene therapies.
What will you learn?
-
Key cell-based assay challenges for bioassays
-
How novel cell-based solutions can help overcome challenges
-
Specific learnings regarding novel cell-based solutions focused on AAV gene therapies
Who may this interest?
-
CGT developers and researchers
-
Biopharmaceutical scientists involved in drug development and testing
-
Bioanalytical scientists working in both pre-clinical and clinical settings
Amruta Kale
Senior Method Development Scientist, Immunochemistry
Labcorp Bioanalytical Services (NC, USA)
Amruta joined Labcorp Bioanalytical Services in 2007 as a member of the Immunochemistry Method Development Team and has developed multiple PK, ADA and NAB (ligand binding and cell-based) methods. Currently, Amruta is a Development Team Lead and assists in the management of development studies in Chantilly, Virginia. Additionally, Amruta has contributed to drafting of global SOPs, assists with site coordination, and provides support to the immunochemistry triage team.
In association with:
